Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-HS LTE
2023-507204-31-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, double-blind, single-arm trial of povorcitinib in hidradenitis suppurativa (HS), sponsored by Incyte. Primary endpoint: Proportion of participants with treatment-emergent adverse events. Planned start Jul 2024; status: authorised.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2023-507204-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507204-31-00.